Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Terapia Tradicional versus Terapia Agressiva Precoce para Teste de Esclerose Múltipla (TREAT-MS)

22 de setembro de 2026 atualizado por: Johns Hopkins University

Um ensaio pragmático para avaliar os efeitos de prazo intermediário da terapia precoce agressiva versus escalonada em pessoas com esclerose múltipla

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.

The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.

The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

Hypotheses/Objectives: The main hypothesis is that intermediate-term disability will be reduced by earlier use of higher-efficacy medications. Additional objectives include a) evaluating the magnitude of the treatment effect in patients deemed to be at higher risk versus lower risk of longer-term disability (we hypothesize that the effect size will be greater in the former group) and b) evaluating if, among those without indications of a high risk of longer-term disability, breakthrough disease can be successfully managed by switching to a different first-line therapy or if escalation is required at that time (we hypothesize that switching to a higher-efficacy therapy will be more effective in preventing disability in this group).

There is a great unmet need to identify the most appropriate treatment strategy for people with MS, especially early in the disease course when it may be possible to maximize an individual's chance for preventing long-term disability. There is a paucity of evidence-based guidelines to help clinicians, patients, and payers determine which treatment strategy is best for an individual with MS. Making treatment decisions is a daunting task, and the individualized benefit-risk assessment becomes increasingly difficult as new therapies emerge. Without the availability of direct comparative trials, clinicians and patients are forced to scrutinize observational studies that only provide basic insights into what may be the best treatment path moving forward. It is equally challenging to define what constitutes a suboptimal response to a DMT for an individual patient. Clinicians lack guidance on when to switch therapies and whether to consider a different first-line or if clinicians should escalate immediately to higher-efficacy therapies, so further consensus is needed to determine the optimal time to switch therapies and escalate therapy if an individual is on a first-line therapy from the start. The TREAT-MS trial will help inform patients and the broader health care community on whether patients would most benefit from early, possibly more risky aggressive therapy or if starting with a less aggressive (and, often, less risky) therapy, followed by a switch if breakthrough disease occurs, is warranted. In addition, this study may help identify specific patient populations and/or short-term clinical and paraclinical biomarkers that are strongly predictive of long-term disability that can ensue from MS.

Accrual of sustained disability is the most feared complication for people with MS, and the patient's own perception of their well-being or ill-being has a profound impact on their quality of life. The heterogeneity and unpredictability of MS, along with lack of agreed upon treatment guidelines, augments this fear, leading to a significant negative impact on quality of life. Even patients who are deemed to have "mild" MS experience a significant negative impact on their health-related quality of life that is similar in magnitude to what patients with other severe chronic conditions (i.e., congestive heart failure and chronic obstructive pulmonary disease) report. An extremely important goal for any intervention is to help improve or maintain a high quality of life; therefore, in addition to classic clinical endpoints (e.g. slowing disability progression), the TREAT-MS trial will capture several important and meaningful PROs that will shed light on what treatment strategies may be the best from a patient-centered perspective.

COVID-19 Related Substudy:

Since early 2020, the coronavirus disease 2019 (COVID-19) pandemic has caused clinical care and research disruptions nationwide, including for patients enrolled in the TREAT-MS trial. Many patients with MS, as well as their clinicians, are fearful that MS or the MS therapy they are using may increase the risk or severity of COVID-19 infection. Whether a person with early MS is more likely to experience more severe COVID-19 if treated with a higher-efficacy therapy is not known. Further, whether COVID-19-induced disruptions in therapy or other clinical care increase MS disease activity or MS symptoms is not clear but is relevant, particularly since greater MS activity in the early therapeutic course is associated in observational studies with worse long-term outcomes. Moreover, it is unclear if pre-pandemic anxiety and depression, common comorbidities in people with MS, contribute to decisions to delay care, overall or differently depending on therapeutic strategy (higher-efficacy vs. traditional). TREAT-MS provides an optimal cohort in which to investigate the effect of the COVID-19 pandemic on MS outcomes.

COVID-19 Substudy Aim 1. To evaluate if patients enrolled in TREAT-MS delayed or altered their disease-modifying therapy schedule or other MS care, and whether such alterations are associated with a greater degree of breakthrough inflammatory disease activity or the development of new (or worsening baseline) MS symptoms.

COVID-19 Substudy Aim 2: To evaluate if patients with MS treated with higher-efficacy, versus traditional, therapies differ in the risk of severe COVID-19 infection, defined as requiring hospitalization (with or without intubation) or mortality due to COVID-19.

Tipo de estudo

Intervencional

Inscrição (Real)

900

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • University of Alabama at Birmingham
      • Mobile, Alabama, Estados Unidos, 36604
        • The University of South Alabama
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85013
        • St. Joseph's Hospital & Medical Center - Barrow Neurological Institute
    • California
      • Carmichael, California, Estados Unidos, 95608
        • CommonSpirit Health Research Institute
      • Los Angeles, California, Estados Unidos, 90095
        • University of California, Los Angeles
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars-Sinai Medical Center
      • San Diego, California, Estados Unidos, 92037
        • University of California, San Diego
      • San Francisco, California, Estados Unidos, 94158
        • University of California, San Francisco
    • Delaware
      • Newark, Delaware, Estados Unidos, 19713
        • Christiana Care Health Services, Inc.
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20007
        • Georgetown University
    • Florida
      • Gainesville, Florida, Estados Unidos, 32611
        • University of Florida
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami
      • Tampa, Florida, Estados Unidos, 33612
        • University of South Florida Health
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Rush University Medical Center
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • The University of Kansas Medical Center (KUMC)
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40207
        • Norton Neurology MS Services
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • The Johns Hopkins Hospital
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland, Baltimore
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Worcester, Massachusetts, Estados Unidos, 01655
        • University of Massachusetts Medical School
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Wayne State University
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • Montana
      • Billings, Montana, Estados Unidos, 59101
        • Billings Clinic
      • Great Falls, Montana, Estados Unidos, 59405
        • Advanced Neurology Specialists
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • University of Nebraska Medical Center
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Hackensack University Medical Center
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center
      • New York, New York, Estados Unidos, 10016
        • New York University School of Medicine
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mount Sinai
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • University of Cincinnati
      • Columbus, Ohio, Estados Unidos, 43214
        • OhioHealth Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Oklahoma Medical Research Foundation
    • Oregon
      • Portland, Oregon, Estados Unidos, 97225
        • Providence Health and Services - Oregon
    • Pennsylvania
      • Danville, Pennsylvania, Estados Unidos, 17822
        • Geisinger Clinic
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212
        • Allegheny Health Network Research Institute
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37215
        • Vanderbilt Comprehensive MS Center
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Baylor Scott and White Health
      • Dallas, Texas, Estados Unidos, 75390-8806
        • University of Texas Southwestern Medical Center
      • Round Rock, Texas, Estados Unidos, 78681
        • Central Texas Neurology Consultants
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • University of Utah
    • Vermont
      • Burlington, Vermont, Estados Unidos, 05405
        • The University of Vermont and State Agricultural College
    • Virginia
      • Christiansburg, Virginia, Estados Unidos, 24073
        • Blacksburg Neurology
      • Norfolk, Virginia, Estados Unidos, 23502
        • Neurology Consultants of Tidewater
    • Washington
      • Seattle, Washington, Estados Unidos, 98122
        • Swedish Health Services
      • Seattle, Washington, Estados Unidos, 98133
        • University of Washington
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of Wisconsin

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Aged 18-60 years
  • Meets 2017 McDonald criteria for relapsing-remitting MS [patients with clinically isolated syndrome (CIS) are not eligible]
  • Must be EITHER John Cunningham (JC) virus antibody negative or low positive (index antibody titer <0.9), OR negative for: Hepatitis B and C, tuberculosis
  • HIV negative
  • No chemotherapy in past year; if patient has prior history of chemotherapy or malignancy, documentation in chart explaining why potential risks of higher-efficacy therapy are justified

Exclusion Criteria:

  • Prior treatment with rituximab, ocrelizumab, ofatumumab, alemtuzumab, mitoxantrone or cladribine
  • Prior treatment with any other MS DMT for more than 6 months
  • Prior treatment with experimental aggressive therapies (e.g., T-cell vaccine, total lymphoid radiation, stem cells)
  • Treatment with teriflunomide within past 2 years (even for ≤ 6 months), unless rapid wash out done (i.e., with cholestyramine or activated charcoal)
  • Treatment in the past 6 months with any MS DMT
  • Prior treatment with any other investigational immune-modulating /suppressing drug for MS not listed above
  • Pregnant or breast-feeding
  • Women of child-bearing age who are planning or strongly considering conception during the study time frame

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Early Aggressive Therapy

Early Aggressive Therapy choices and maximum allowable doses:

  • Natalizumab/natalizumab-sztn (Tysabri/Tyruko), 300 mg IV q 4 wks
  • Alemtuzumab (Lemtrada), 12 mg IV daily (QD) for 5 days; 1 yr later: 12 mg IV QD for 3 days
  • Ocrelizumab (Ocrevus), 300 mg IV every 2 wks (for 2 doses) at initiation; 600 mg IV q 6 mths
  • Rituximab/rituximab biosimilars (Rituxan/Riabni/Truxima/Ruxience), 1000 mg IV every 2 wks (for 2 doses); may repeat q 16-24 wks
  • Cladribine (Mavenclad), 3.5 mg per kg body wt orally divided into 2 yrly tmt courses (1.75 mg per kg body wt each yr); yrly tmt course divided into 2 tmt cycles; administer cycle dose as 1-2 tablets QD over 4-5 days
  • Ofatumumab (Kesimpta), 20 mg SC wkly for wks 0, 1 and 2; 20 mg subcutaneously (SC) mthly starting at wk 4
  • Ublituximab-xiiy (Briumvi), 150 mg IV (1st dose); 450 mg IV 2 wks after first dose; 450 mg IV q 24 wks
  • Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), 920 mg ocrelizumab and 23,000 U hyaluronidase SC q 6 months
Outro: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq

Early Aggressive Therapy

Outros nomes:
  • Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo
Comparador Ativo: Traditional Therapy

Traditional Therapy choices and maximum allowable doses:

  • Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg SC daily, or 40 mg SC 3 times a wk
  • Intramuscular (IM) interferon (Avonex), 30 mcg IM weekly
  • SC interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC 3 times a wk (Rebif)
  • Pegylated interferon (Plegridy), 125 mcg SC every 14 days
  • Teriflunomide (Aubagio), 14 mg PO QD
  • Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day (BID)
  • Diroximel fumarate (Vumerity), 462 mg PO BID
  • Monomethyl fumarate (Bafiertam), 190 mg PO BID
  • Fingolimod (Gilenya and generics), 0.5 mg PO QD
  • Siponimod (Mayzent), 1 mg PO QD or 2 mg PO QD
  • Ozanimod (Zeposia), 0.92 mg PO QD
  • Ponesimod (Ponvory), 20 mg PO QD
  • Fingolimod ODT (Tascenso), 0.25 mg PO QD if <=40 kg; 0.5 mg PO QD if > 40 kg
Outro: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod

Traditional Therapy

Outros nomes:
  • Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Time to sustained disability progression
Prazo: From date of randomization until the date of first documented sustained disability progression, up to 99 months

Time to sustained disability progression is measured by the Expanded Disability Status Scale plus (EDSS+): a composite endpoint that includes EDSS change (change at any 6 month time point of > or = 1.0 point if baseline EDSS is < or = 5.5 or of > or = 0.5 if baseline EDSS is > or = 6.0, that is sustained 6 months later) OR 20% worsening on either of two specific components of the Multiple Sclerosis Functional Composite (MSFC), the timed 25-foot walk test (T25FWT) and the nine hole peg test (9HPT) that is sustained 6 months later.
From date of randomization until the date of first documented sustained disability progression, up to 99 months
Change in Overall Burden of MS
Prazo: up to 48 weeks from enrollment into COVID-19 related substudy

The change in overall burden of MS will be defined for the COVID-19 related substudy as the occurrence of breakthrough disease (relapses or new MRI activity) or the development of new (or worsening baseline) MS symptoms, which are (for TREAT-MS) and will continue to be (during the substudy) documented at clinical visits, whether in-person or on tele-visits.
up to 48 weeks from enrollment into COVID-19 related substudy

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Patient-Determined Disease Steps (PDDS)
Prazo: up to 99 months

PDDS is a self-assessment scale of disability due to MS on a scale from 0 to 8 and will be administered as an electronic patient-reported outcome (PRO).
up to 99 months
Multiple Sclerosis Functional Composite (MSFC) Composite Score
Prazo: up to 99 months

The MSFC consists of the timed 25 foot walk test, the 9-hole peg test, and the Paced Auditory Serial Addition Test (PASAT) and a composite MSFC z-score will be evaluated.
up to 99 months
Timed 25 Foot Walk Test
Prazo: up to 99 months

Time taken to complete the timed 25 foot walk test, measured twice in units of seconds, will be averaged and evaluated.
up to 99 months
Nine-hole Peg Test
Prazo: up to 99 months

Time taken to complete the nine-hole peg test, measured twice for each hand (dominant and non-dominant) in units of seconds, will be averaged for each hand and evaluated.
up to 99 months
Paced Auditory Serial Addition Test (PASAT)
Prazo: up to 99 months

The paced auditory serial addition test that measures processing speed will be administered once; number and percent correct will be evaluated.
up to 99 months
Low contrast visual acuity
Prazo: up to 99 months

Low-contrast letter acuity (binocular, 2.5% contrast Sloan charts)
up to 99 months
Patient-reported incomplete relapse recovery
Prazo: up to 99 months

Among participants identified to have a relapse, relapse recovery will be defined as complete or incomplete based on patient self-report.
up to 99 months
Neurologic exam-based incomplete relapse recovery
Prazo: up to 99 months

Among participants identified to have a relapse, relapse recovery will be defined as complete or incomplete based on neurologic examination (those who have increased Functional System scores, corresponding to the relapse symptoms, of 1.0 point or greater for at least 6 months after the relapse onset, without subsequent accrual of worsening in that same Functional System (e.g. more indicative of progression), will be considered to have incomplete relapse recovery).
up to 99 months
Cognition using Symbol Digit Modality Test (SDMT)
Prazo: up to 99 months

The SDMT is commonly used in MS to assess processing speed and will be administered orally and used to evaluate changes in cognition throughout the study.
up to 99 months
Multiple Sclerosis Impact Scale (MSIS-29)
Prazo: up to 99 months

The MSIS-29 will be used to evaluate the impact of MS on the participants and will be administered as an electronic PRO.Multiple Sclerosis Impact Scale (MSIS-29) is an instrument used for measuring the physical (20 items) and psychological (nine items) impact of multiple sclerosis.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Anxiety Subscale
Prazo: up to 99 months

The Anxiety Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Depression Subscale
Prazo: up to 99 months

The Depression Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Fatigue Subscale
Prazo: up to 99 months

The Fatigue Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Upper Extremity Function
Prazo: up to 99 months

The Upper Extremity Function Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Lower Extremity Function
Prazo: up to 99 months

The Lower Extremity Function Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Cognitive Function
Prazo: up to 99 months

The Cognitive Function Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Positive Affect/Well-being
Prazo: up to 99 months

The Positive Affect/Well-being Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Sleep Disturbance
Prazo: up to 99 months

The Sleep Disturbance Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Ability to Participate in Social Roles and Activities
Prazo: up to 99 months

The Ability to Participate in Social Roles and Activities Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Satisfaction with Social Roles and Activities
Prazo: up to 99 months

The Satisfaction with Social Roles and Activities Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Stigma
Prazo: up to 99 months

The Stigma Subscale of Neuro-QoL will be administered as an electronic PRO.
up to 99 months
Employment status
Prazo: up to 99 months

The incidence of change in employment to "disabled" or "looking for work, unemployed," will be evaluated for all participants through an electronic PRO.
up to 99 months
Marital status
Prazo: up to 99 months

Incident divorce or separation, among those who previously were married or in a domestic partnership, will be evaluated for all participants through an electronic PRO.
up to 99 months
Serious Adverse Events (SAEs)
Prazo: up to 99 months

SAEs (clinically significant infections, malignancies, or the development of other serious comorbidities, as well as unplanned hospitalizations [for non-elective issues, excluding MS relapse] and death)
up to 99 months
Adverse event resulting in a decision to change disease-modifying therapy
Prazo: up to 99 months

Adverse events meaningful enough to lead to medication discontinuation
up to 99 months
Severe COVID-19 Infection
Prazo: up to 48 weeks from enrollment into COVID-19 related substudy

Severe COVID-19 infection will be defined as an outcome of "hospitalization or death" due to confirmed or suspected COVID-19 infection
up to 48 weeks from enrollment into COVID-19 related substudy

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Johns Hopkins University

Colaboradores

Patient-Centered Outcomes Research Institute
National Multiple Sclerosis Society

Investigadores

  • Investigador principal: Ellen M. Mowry, MD, MCR, Johns Hopkins University
  • Investigador principal: Scott D. Newsome, DO, Johns Hopkins University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

2 de maio de 2018

Conclusão Primária (Real)

31 de julho de 2026

Conclusão do estudo (Real)

31 de agosto de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

21 de fevereiro de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de abril de 2018

Primeira postagem (Real)

18 de abril de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • IRB00143534

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever